Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct 1;15(10):469.
doi: 10.3390/jpm15100469.

Implementation of an Alzheimer's Disease Blood Test: Adoption Experience by Memory Care Specialists in a Multi-Center Study

Mark Monane  1 , Robert M Carlile  2 , Kim G Johnson  3 , Darren R Gitelman  4   5 , Lawren A VandeVrede  6 , Demetrius M Maraganore  7 , David A Merrill  8 , Leslie Jacobs  1 , Justine Coppinger  1 , Philip B Verghese  1 , Tim West  1 , Joel B Braunstein  1
Affiliations

Implementation of an Alzheimer's Disease Blood Test: Adoption Experience by Memory Care Specialists in a Multi-Center Study

Mark Monane et al. J Pers Med. .

Abstract

Background/Objectives: A high-performing blood biomarker (BBM) test for Alzheimer's disease (AD) represents an accurate, accessible, and scalable tool to aid healthcare professionals (HCPs) evaluating patients presenting with signs or symptoms of mild cognitive impairment (MCI) or dementia. However, implementation of AD blood tests into clinical practice has not been extensively evaluated. The objective of this study was to assess the implementation of the multi-analyte PrecivityAD2™ blood test (C2N Diagnostics, LLC, St. Louis, MO, USA) into the clinical workflow of memory care clinics. Methods: A total of 8 HCPs (neurologists, geriatricians, geriatric psychiatrists) who served as site directors from 8 outpatient sites that evaluated 203 cognitively symptomatic patients were included in this sub-study of the real-world QUIP II Study (NCT06025877). Implementation of this blood test was assessed through surveying these HCPs using published frameworks including the Technology Acceptance Model, net promoter score, and forced choice preference questions. These assessments were analyzed using Wilcoxon signed-rank test, Fisher's Exact test, and Wilcoxon signed-rank test, respectively. Results: HCPs reported acceptance scores that averaged 9.6 out of 10 (p < 0.0001, effect size 0.840): the test's contribution to clinical decision-making as well as the ease of understanding test results received the highest ratings. The net promoter score was 75 (p < 0.0001), exceeding the typical benchmark of 30 reported as good levels of satisfaction in healthcare settings. The APS2 results and individual blood analyte results were rated with similar preference around their roles in HCP clinical decision-making. Conclusions: The results indicate early evidence of user acceptance and recognition by HCPs that this AD blood test can personalize the clinical care pathway for evaluating cognitively symptomatic patients.

Keywords: Alzheimer’s disease; blood biomarker; clinical decision-making; dementia; implementation; memory care specialists; mild cognitive impairment; personalized medicine.

PubMed Disclaimer

Conflict of interest statement

Matt Carlile has received Speakers Bureau payments from AbbVie, Lilly, and Teva. Darren Gitelman has received grants or contracts from Alzheimer’s Association, Biogen, Bristol Myers Squibb, Cassava, Davos Alzheimer’s Collaborative, Eisai, and Lilly. He has received consulting fees from AbbVie, Eisai, and Lilly. Kim Johnson has received research funding from Alzheimer’s Association, Athira, Annovis, Eisai, LEXEO Pharmaceuticals, and The Critical Path Institute. She has received consulting fees from Lilly and the University of Southern California and has served on a Lilly Advisory Board for clinical implementation of anti-amyloid therapy. She has received payment or honoraria from Eisai and PeerView. Lawren VandeVrede has received research support from the Alzheimer’s Association, National Institute of Health, and Shenandoah Foundation and is serving as the principal investigator for clinical trials sponsored by Merck and Biogen. He has received consulting fees from Biogen, Roche, and Siemens. Joel Braunstein, Justine Coppinger, Leslie Jacobs, Mark Monane, Philip Verghese and Tim West are salaried employees or consultants, and Joel Braunstein, Mark Monane, Philip Verghese and Tim West have equity interests in C2N Diagnostics, LLC. Demetrius Maraganore and David Merrill have no competing interests. C2N Diagnostics, LLC provided study implementation and management support.

References

    1. Drugan T., Leucuța D. Evaluating Novel Biomarkers for Personalized Medicine. Diagnostics. 2024;14:587. doi: 10.3390/diagnostics14060587. - DOI - PMC - PubMed
    1. Palmqvist S., Tideman P., Mattsson-Carlgren N., Schindler S.E., Smith R., Ossenkoppele R., Calling S., West T., Monane M., Verghese P.B., et al. Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care. JAMA. 2024;332:1245–1257. doi: 10.1001/jama.2024.13855. - DOI - PMC - PubMed
    1. Mattke S., Jun H., Chen E., Liu Y., Becker A., Wallick C. Expected and diagnosed rates of mild cognitive impairment and dementia in the U.S. Medicare population: Observational analysis. Alzheimers Res. Ther. 2023;15:128. doi: 10.1186/s13195-023-01272-z. - DOI - PMC - PubMed
    1. Rabinovici G.D., Knopman D.S., Arbizu J., Benzinger T.L.S., Donohoe K.J., Hansson O., Herscovitch P., Kuo P.H., Lingler J.H., Minoshima S., et al. Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. Alzheimers Dement. 2025;21:e14338. doi: 10.1002/alz.14338. - DOI - PMC - PubMed
    1. Palmqvist S., Zetterberg H., Mattsson N., Johansson P., The Alzheimer’s Disease Neuroimaging Initiative. Minthon L., Blennow K., Olsson M., The Swedish BioFINDER Study Group. Hansson O. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology. 2015;85:1240–1249. doi: 10.1212/WNL.0000000000001991. - DOI - PMC - PubMed

LinkOut - more resources